Start Licensing, Inc. (Start) announced that it controls key patents in Korea that obscure carnal cloning technology, including the technology used to clone dogs. RNL Bio Ltd (RNL) announced on February 12, 2008 that it was launching a dog cloning service and had signed its first client. RNL is not licensed under Start’s patents. These patents include Korean Grant Nos. 10-0533476, 10-0533477, and 10-0743006, and are part of a portfolio of patents and patent applications owned by Roslin Institute that are directed to foundational somatic cell atomic transfer (SCNT) cloning technology developed at Roslin Institute for the cloning of Dolly the sheep. This portfolio is exclusively licensed to Start for all non-benefactor animal cloning applications.

“Start will shelter its patent rights,” said Jonathan Thatcher, President of Start Licensing. “We hand down grab all inexorable actions and one’s addresses to every available legal remedy to do so.”

Impotencia masculina

Here Start Licensing

Start is a joint hazardous undertaking of Geron Corporation (Nasdaq: GERN) and Exeter Life Sciences, Inc. Start manages and licenses a frank portfolio of intellectual property rights consanguineous to animal reproductive technologies, including foundational nuclear hand on cloning technology developed at the Roslin Start towards the cloning of Dolly the sheep. Start’s licensees are on the cutting edge of check out and product growth in food origination, medical applications and many other fields.

Geron Corporation

This entry was posted on Tuesday, February 2nd, 2010 at 8:04 am and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.